Injectables and Implantables
制御放出 (CR) や長期放出 (PR) のための注射剤や植込み型医療機器の開発は、近年になって大きく進展してきました。その結果、患者の自由度が高まり、アドヒランス (患者の服薬遵守) の改善も見られる、という成果も出てきています。注射剤や植込み型医療機器は、今後の医薬品・医療機器の業界に大きな市場機会を与えると期待されています。他方、費用負担や規制認証、十分なエビデンスの蓄積、新興国での普及浸透など、克服すべき課題も山積しています。
当レポートでは、注射剤と植込み型医療機器 - 今日のドラッグデリバリー (薬剤送達) の重要な要素 - の最新の技術・市場動向について分析し、業界関係者へのヒアリングに基づいて、その期待されている効果や、特に効果が高い治療領域、これから解決すべき諸問題、将来の市場機会の大きさ・方向性などについて調査・考察しております。
The development of controlled and prolonged release injectable and implantable drugs has seen huge leaps forward in recent years. Increasing prevalence of chronic diseases; innovative technological advancements; growth in complex therapies such as biologics: together these factors create the potential for drug delivery solutions which offer greater patient freedom and improved adherence. Which disease areas offer the best opportunities for injectables and implantables? And what is the current position on core issues such as reimbursement, real world evidence and regulation? Now you can find out the answers to these crucial questions and more.
This report offers an up-to-date view of the fast-developing injectables and implantables market, identifying the key opportunities as well as recognising the challenges and barriers facing pharma companies looking to invest in this promising area. Delving into a wide range of issues from regulation to real world evidence to ethics and social constraints, The FutureViews Injectables and Implantables report provides the experts' view of the market to inform current and future investment strategy.
" If pharma is to provide access to injectables/implantables to emerging markets, it must address storage issues and social barriers. Many lower- and middle-income countries are also in regions of the world where elevated temperatures that would require cold storage for biologics. Injectables/implantables will also require aseptic facilities of manufacturing. Without adequate storage and aseptic facilities, medicines could be at risk for contamination. Additionally, manufacturers may encounter social and religious barriers to the use of some medicines such as contraceptives and vaccines: these must first be identified so that pharma can adopt storage-friendly formulations and devise culturally sensitive solutions to adoption barriers."
"Like all novel technologies entering the medical marketplace, clinician and patient adoption is indicative of a successful product. The pharma market can do a lot to help educate and provide useful information to the public regarding the benefits and patient outcomes from utilising new technologies that are entering the marketplace in the space of drug delivery. The key to knowledge is spreading awareness." Idicula Mathew , Co-Founder & CEO, Hera Health Solutions, US.
Improving adherence is one of the biggest challenges facing pharma; it's also perhaps the most powerful benefit of injectables and implantables. Longer lasting medication means less frequent delivery, which in turn means fewer physician appointments and fewer lapses. More discrete administering of drugs is obviously preferable for patients. Injectables and implantables offer a way forward that is far easier and more convenient for all, and enables physicians to offer a holistic response as well as improved health outcomes.